Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., Lord, J., Middleton, C., Szlosarek, P., Chan, S., Gaba, A., Darlison, L., Wells-Jordan, P., Richards, C., Poile, C., Lester, J. F., Griffiths, G., , , Price, G., Shaw, P., Cave, J., Naik, J., Ford, A., Geldhart, T., Dancey, G., Papadatos, D., Polychronis, A., Jankowska, P., Scott, A., Gardiner, J., Cominos, M., Campbell, L., MacGregor, C., Mullholand, L., Chitnis, M., & Dougherty, G. (2021). nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet oncology, 22(11), 1530–1540. http://access.bl.uk/ark:/81055/vdc_100145644182.0x00000d